Albany, NY -- (SBWire) -- 01/21/2019 --Hepatocellular carcinoma (HCC) is the most common type of liver cancer. It is the sixth most common type of cancer, accounts for around 90% of primary liver cancers, and is third most common cause of cancer mortality. HCC is particularly aggressive and has a poor survival rate (five-year survival <5%) and therefore remains an important public health issue worldwide. In Asia and Africa, factors for development include Hepatitis B and C infection, aflatoxin exposure (from crops), liver cirrhosis and hemochromatosis, while in developed countries, factors for development include diabetes, obesity and non-alcoholic steatohepatitis (NASH). For unresectable HCC, the standard of care, Bayers Nexavar (sorafenib), prolongs survival by just three months, therefore more treatment options are needed.

This report provides an assessment of the pipeline, clinical, and commercial landscape of HCC. Overall, GlobalData expects new drug approvals to drive HCC market growth over the next decade (2016-2026).

Request a Sample PDF with Tables and Figures: https://www.researchmoz.us/enquiry.php?type=S&repid=1978207

Scope

- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
- Clinical Trial Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
- Commercial Assessment: leading marketed products, current and future players
- Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HCC market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HCC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

View Complete TOC with Tables and Figures at: https://www.researchmoz.us/hepatocellular-carcinoma-competitive-landscape-to-2026-report.html/toc

About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us